Novavax (NVV1) Price & Analysis

Compare

8 Followers

NVV1 Stock Chart & Stats

€7.35

-€1.01(-9.65%)

At close: Jan 08 4:00 PM EST

€7.35

-€1.01(-9.65%)

Day’s Range― - ―

52-Week Range€4.82 - €8.57

Previous CloseN/A

Volume7.16K

Average Volume (3M)3.90K

Market Cap

€1.20B

Enterprise Value€1.40B

Total Cash (Recent Filing)€762.89M

Total Debt (Recent Filing)€251.14M

Price to Earnings (P/E)4.2

Beta2.72

Next Earnings

Feb 26, 2026

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.06

Shares Outstanding162,499,000

10 Day Avg. Volume1,890

30 Day Avg. Volume3,905

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)-1.96

Price to Sales (P/S)1.79

P/FCF Ratio-12.20

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€10.34

Price Target Upside40.74% Upside

Rating ConsensusHold

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Partner Validation For Matrix-MA non-exclusive license from a major pharmaceutical company signals external validation of Matrix-M's commercial value and could attract further partnerships and licensing opportunities.

Pipeline Competitiveness In RSV And ShinglesMatrix-M's potential to enhance vaccine performance in RSV and shingles could strengthen the company's internal programs and shift competitive dynamics in these markets.

Revenue Model With Reduced Commercialization RiskAgreements that have partners handle development and commercialization while the company supplies Matrix-M create a revenue stream through upfront payments, milestones and royalties without bearing full commercialization costs.

Bears Say

Dependence On Late-stage Development MilestonesFinancial upside is tied to late-stage trial successes and commercialization milestones whose timing and likelihood remain uncertain, leaving valuation exposed to binary clinical outcomes.

Limited Near-term Collaboration RunwayA shortage of Matrix-M collaboration programs approaching clinical trials limits near-term revenue visibility and increases reliance on a small number of advancing partnerships.

Soft COVID Demand And Seasonal RiskWeak script trends and reduced expectations for COVID vaccine demand, alongside the possibility of stricter seasonal vaccine requirements, could pressure sales and investor sentiment for vaccine-focused companies.

Novavax News

Novavax Soars as Traders Bet Big on Vaccine Future

Novavax ( ($NVAX) ) has risen by 14.48%. Read on to learn why. Novavax shares climbed 14.48% over...

27d ago

NVAX

Novavax call volume above normal and directionally bullish

Bullish option flow detected in Novavax (NVAX) with 15,177 calls trading, 3x expected, and implied vol increasing almost...

1M ago

NVAX

Novavax: Execution Risks, Long-Dated Cash Flows, and COVID Market Headwinds Undermine Profitability Outlook

Analyst Alec Stranahan of Bank of America Securities reiterated a Sell rating on Novavax, boosting the price target...

1M ago

NVAX

Novavax: Pfizer Partnership Validates Matrix‑M Platform and Supports Upside in Capital‑Light Growth Strategy

Analyst Thomas Shrader of BTIG maintained a Buy rating on Novavax, with a price target of $19.00. Thomas...

1M ago

NVAX

Novavax price target raised to $7 from $6 at BofA

BofA raised the firm’s price target on Novavax (NVAX) to $7 from $6 and keeps an Underperform rating...

1M ago

PFE

NVAX

Novavax: Expanding Matrix-M Licensing Partnerships Drive Upside Potential and Support Buy Rating

Novavax, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Sean Lee CFA from...

1M ago

NVAX

Novavax enters license agreement with Pfizer for use of Matrix-M

Novavax (NVAX) has entered into a license agreement with Pfizer (PFE) for use of Novavax’s Matrix-M adjuvant. Under...

1M ago

PFE

NVAX

Novavax Outlines New Growth Strategy and Partnerships

Novavax ( ($NVAX) ) has provided an announcement. Novavax plans to provide investors with strategic and business updates...

1M ago

NVAX

Vaccine committee considers changes to childhood schedule, NY Times reports

Advisers to Health Secretary Robert F. Kennedy Jr. are considering major revisions to the childhood vaccination schedule, including...

3M ago

AZN

BMY

MRNA, NVAX, BNTX: Here’s What Triggered a Sell-off in Major Vaccine Stocks Today

Shares of major COVID-19 vaccine makers, Moderna ($MRNA), BioNTech ($BNTX), and Novavax ($NVAX) fell 6%, 5%, and 4%,...

3M ago

BNTX

MRNA

Prasad email a headwind for vaccine manufacturers, says BofA

BofA notes that a leaked email from CBER director Dr. Vinay Prasad detailing that staff have reportedly found...

3M ago

GSK

PFE

Video: Vaccine makers slide following report of leaked memo from FDA’s Prasad

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

3M ago

LEG

Morning Movers: Synopsys leaps following Nvidia investment

Markets are opening in a cautious mood with index futures drifting lower as investors await fresh economic data...

3M ago

LEG

Prasad ties 10 children deaths to COVID vaccines in leaked memo, STAT reports

The Food and Drug Administration’s top vaccine regulator, Vinay Prasad, director of the FDA’s Center for Biologics Evaluation...

3M ago

AZN

PFE

NVV1 FAQ

What was Novavax’s price range in the past 12 months?

Novavax lowest stock price was €4.82 and its highest was €8.57 in the past 12 months.

What is Novavax’s market cap?

Novavax’s market cap is €1.20B.

When is Novavax’s upcoming earnings report date?

Novavax’s upcoming earnings report date is Feb 26, 2026 which is in 6 days.

How were Novavax’s earnings last quarter?

Novavax released its earnings results on Nov 06, 2025. The company reported -€1.063 earnings per share for the quarter, missing the consensus estimate of -€1.017 by -€0.046.

Is Novavax overvalued?

According to Wall Street analysts Novavax’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novavax pay dividends?

Novavax does not currently pay dividends.

What is Novavax’s EPS estimate?

Novavax’s EPS estimate is -0.42.

How many shares outstanding does Novavax have?

Novavax has 162,499,000 shares outstanding.

What happened to Novavax’s price movement after its last earnings report?

Novavax reported an EPS of -€1.063 in its last earnings report, missing expectations of -€1.017. Following the earnings report the stock price went up 3.398%.

Which hedge fund is a major shareholder of Novavax?

Currently, no hedge funds are holding shares in DE:NVV1

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Novavax Stock Smart Score

Underperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

-31.10%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Novavax

Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Novavax (NVV1) Earnings & Revenues

Historic Earnings Reports

NVV1 Company Deck

NVV1 Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted significant progress in strategic partnerships, cost reduction efforts, and financial improvements. However, there were notable challenges, including decreased product sales and a considerable net loss. The positive aspects slightly outweigh the negative, indicating a cautiously optimistic outlook.View all DE:NVV1 earnings summaries

NVV1 Stock 12 Month Forecast

Average Price Target

€10.34

▲(40.74% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","17":"€17","7.25":"€7.25","10.5":"€10.5","13.75":"€13.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":16.11039184,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€16.11</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":10.344567392,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€10.34</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":5.08749216,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€5.09</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,7.25,10.5,13.75,17],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.405,8.074645526153846,8.744291052307693,9.413936578461538,10.083582104615385,10.75322763076923,11.422873156923076,12.092518683076921,12.762164209230768,13.431809735384615,14.10145526153846,14.771100787692305,15.440746313846152,{"y":16.11039184,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.405,7.631120568615385,7.857241137230769,8.083361705846155,8.309482274461539,8.535602843076923,8.761723411692309,8.987843980307693,9.213964548923077,9.440085117538462,9.666205686153846,9.89232625476923,10.118446823384616,{"y":10.344567392,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.405,7.226730166153846,7.048460332307693,6.870190498461539,6.691920664615385,6.513650830769231,6.335380996923077,6.157111163076923,5.97884132923077,5.800571495384616,5.622301661538462,5.444031827692308,5.265761993846154,{"y":5.08749216,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.594,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.813,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.695,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.626,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.342,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.341,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.746,"date":1754006400000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":6.256,"date":1756684800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.256,"date":1759276800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 30, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.97,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 36, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":5.734,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 60, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":7.405,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 41, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >